Ruxolitinib, a potent JAK1/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent CSF3R mutations in chronic neutrophilic leukemia

Shranjeno v:
Bibliografske podrobnosti
izdano v:Haematologica
Main Authors: Gunawan, Arief S., McLornan, Donal P., Wilkins, Bridget, Waghorn, Katherine, Hoade, Yvette, Cross, Nicholas C. P., Harrison, Claire N.
Format: Artigo
Jezik:Inglês
Izdano: Ferrata Storti Foundation 2017
Teme:
Online Only Articles
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5451352/
https://ncbi.nlm.nih.gov/pubmed/28302714
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2017.163790
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki